全文获取类型
收费全文 | 1369篇 |
免费 | 106篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 88篇 |
妇产科学 | 13篇 |
基础医学 | 154篇 |
口腔科学 | 51篇 |
临床医学 | 194篇 |
内科学 | 242篇 |
皮肤病学 | 24篇 |
神经病学 | 79篇 |
特种医学 | 283篇 |
外科学 | 107篇 |
综合类 | 38篇 |
一般理论 | 1篇 |
预防医学 | 44篇 |
眼科学 | 20篇 |
药学 | 60篇 |
中国医学 | 5篇 |
肿瘤学 | 74篇 |
出版年
2023年 | 9篇 |
2022年 | 3篇 |
2021年 | 9篇 |
2020年 | 7篇 |
2019年 | 13篇 |
2018年 | 24篇 |
2017年 | 14篇 |
2016年 | 22篇 |
2015年 | 25篇 |
2014年 | 31篇 |
2013年 | 34篇 |
2012年 | 51篇 |
2011年 | 44篇 |
2010年 | 48篇 |
2009年 | 66篇 |
2008年 | 48篇 |
2007年 | 37篇 |
2006年 | 42篇 |
2005年 | 25篇 |
2004年 | 28篇 |
2003年 | 33篇 |
2002年 | 26篇 |
2001年 | 33篇 |
2000年 | 33篇 |
1999年 | 24篇 |
1998年 | 55篇 |
1997年 | 54篇 |
1996年 | 65篇 |
1995年 | 50篇 |
1994年 | 52篇 |
1993年 | 50篇 |
1992年 | 20篇 |
1991年 | 19篇 |
1990年 | 24篇 |
1989年 | 42篇 |
1988年 | 41篇 |
1987年 | 41篇 |
1986年 | 38篇 |
1985年 | 30篇 |
1984年 | 18篇 |
1983年 | 12篇 |
1982年 | 23篇 |
1981年 | 19篇 |
1980年 | 15篇 |
1979年 | 11篇 |
1978年 | 7篇 |
1977年 | 18篇 |
1976年 | 20篇 |
1975年 | 14篇 |
1971年 | 3篇 |
排序方式: 共有1482条查询结果,搜索用时 15 毫秒
1.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
2.
We describe 2 renal transplant patients with increasing plasma creatinine levels after resolution of acute rejection episodes. Antegrade pyelography demonstrated adherence of the ureter to the inferior pole of the kidney with partial obstruction in both cases, which was confirmed at operation. 相似文献
3.
It is known that low glucose concentrations increase the aspartate and decrease the glutamate content of brain tissue both in vivo and in vitro. To see whether these changes occur in the transmitter compartment or not, the release of aspartate and glutamate evoked by electrical-field stimulation or by high K+ was followed in slices of rat hippocampus superfused with 5 or 0.2 mM glucose. Superfusion with 0.2 mM glucose increased the evoked release of aspartate about ten times and that of glutamate about threefold. This shift in the ratio of aspartate to glutamate released was accompanied by a similar increase in the relative amount of aspartate contained in the slices. The high evoked release of aspartate and glutamate was well maintained, provided 0.5 mM glutamine was added to the medium. Changing the concentration of glucose after the first period of stimulation rapidly altered the relative amounts of aspartate and glutamate released but not the enhanced release of glutamate. The large evoked release of both aspartate and glutamate in 0.2 mM glucose was almost entirely Ca2+-dependent. The relative amounts of aspartate and glutamate released by 50 mM K+ also changed when the glucose concentration was reduced. Results suggest two effects of low glucose concentrations: an increase in the overflow of synaptically released glutamate due to a decreased uptake and an increase in the proportion of aspartate to glutamate formed and released from the transmitter pool. These observations are consistent with the interpretation that these two transmitters can be released in different proportions from the same terminals. 相似文献
4.
5.
6.
7.
8.
9.
10.